284 related articles for article (PubMed ID: 37467684)
1. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
[TBL] [Abstract][Full Text] [Related]
2. Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?
Huguet F; Durand B; Atallah S; Prébet C; Richard S; Baujat B
Cancer Radiother; 2021 Dec; 25(8):811-815. PubMed ID: 34711485
[TBL] [Abstract][Full Text] [Related]
3. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
4. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.
Vanderveken OM; Szturz P; Specenier P; Merlano MC; Benasso M; Van Gestel D; Wouters K; Van Laer C; Van den Weyngaert D; Peeters M; Vermorken J
Oncologist; 2016 Jan; 21(1):59-71. PubMed ID: 26712958
[TBL] [Abstract][Full Text] [Related]
6. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Taberna M; Oliva M; Mesía R
Front Oncol; 2019; 9():383. PubMed ID: 31165040
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
9. Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists.
Xing DT; Khor R; Gan H; Wada M; Ermongkonchai T; Ng SP
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830871
[TBL] [Abstract][Full Text] [Related]
10. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
[TBL] [Abstract][Full Text] [Related]
11. A bioconvergence study on platinum-free concurrent chemoradiotherapy for the treatment of HPV-negative head and neck carcinoma.
Gonnelli A; Sarogni P; Giannini N; Linsalata S; Di Martino F; Zamborlin A; Frusca V; Ermini ML; Puccini P; Voliani V; Paiar F
Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):122-129. PubMed ID: 38315518
[TBL] [Abstract][Full Text] [Related]
12. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
[TBL] [Abstract][Full Text] [Related]
14. Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific.
Guo Y; Nakashima T; Cho BC; Lim DW; Yang MH; Lou PJ; Corry J; Lin JC; Zhu GP; Kim KH; Zhang B; Li Z; Hong RL; Ng JYS; Tan EM; Liu YP; Stylianou C; Spiteri C; Porceddu S
Oral Oncol; 2024 Jan; 148():106657. PubMed ID: 38101313
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
Sun L; Candelieri-Surette D; Anglin-Foote T; Lynch JA; Maxwell KN; D'Avella C; Singh A; Aakhus E; Cohen RB; Brody RM
JAMA Otolaryngol Head Neck Surg; 2022 Nov; 148(11):1022-1028. PubMed ID: 36136306
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Study of the CDK4/6 Inhibitor Palbociclib in Combination with Cetuximab and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Ngamphaiboon N; Pattaranutaporn P; Lukerak S; Siripoon T; Jinawath A; Arsa L; Shantavasinkul PC; Taonam N; Trachu N; Jinawath N; Kositwattanarerk A; Sananmuang T; Jiarpinitnun C
Clin Cancer Res; 2024 Jan; 30(2):294-303. PubMed ID: 37982827
[TBL] [Abstract][Full Text] [Related]
17. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
19. HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.
McLaughlin M; Barker HE; Khan AA; Pedersen M; Dillon M; Mansfield DC; Patel R; Kyula JN; Bhide SA; Newbold KL; Nutting CM; Harrington KJ
BMC Cancer; 2017 Jan; 17(1):86. PubMed ID: 28143445
[TBL] [Abstract][Full Text] [Related]
20. De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
Lorini L; Gili R; Salvestrini V; Morelli I; Smussi D; Petrelli F; Bonomo P; Bossi P
Oral Oncol; 2024 May; 152():106768. PubMed ID: 38552469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
